Hexarelin 10mg/vial 1 Vial by Bio-Peptide

Usage

1. Reconstitute carefully: Add 1–2 mL of bacteriostatic water to the lyophilised Hexarelin powder by injecting the water slowly down the inner vial wall — never directly onto the powder — to prevent peptide denaturation from foaming.
2. Calculate your dose: At 10 mg per vial with 2 mL bacteriostatic water, each 0.1 mL drawn into an insulin syringe equals 500 mcg; adjust the drawn volume proportionally to your target dose (e.g., 0.02 mL = 100 mcg).
3. Administer subcutaneously: Inject into the subcutaneous fat of the abdomen or thigh using a 29–31-gauge insulin syringe; administer in a fasted state (minimum 90 minutes post-meal) to avoid somatostatin blunting of the GH pulse.
4. Time injections around rest periods: To capitalise on Hexarelin's sharp GH pulse, the pre-sleep injection is the highest-priority dose, coinciding with the endogenous nocturnal GH surge.
5. Monitor for early desensitisation signs: If subjective GH-response indicators (e.g., water retention, sleep quality shifts) diminish within the first three weeks, advance the tolerance-break phase rather than increasing dose — escalation accelerates receptor downregulation further.
6. Store reconstituted vials at 2–8 °C: and discard after 21–28 days; keep unreconstituted vials sealed, away from direct light, and at stable room temperature until needed.

Warnings

Frequently asked questions

Why is Hexarelin considered the strongest GHRP available for research?

Hexarelin is the most potent GHRP because it activates GHS-R1a with sub-nanomolar affinity and simultaneously engages a secondary ghrelin-independent GH-secretion pathway — a dual mechanism not shared by GHRP-2 or GHRP-6. This produces significantly larger acute GH pulses at equivalent doses. Receptor-binding data and clinical GH-secretion studies (Ghigo et al., 1994) consistently place Hexarelin at the top of the GHRP potency ranking.

How quickly does Hexarelin desensitisation develop compared to other GHRPs?

Desensitisation to Hexarelin can develop within two to four weeks of continuous daily dosing — faster than any other GHRP in the class. Compared to GHRP-6, where receptor accommodation is more gradual, Hexarelin's downregulation is compressed due to its high receptor affinity and potency. Researchers document measurable GH blunting in human subjects by week three of uninterrupted administration, making rest periods non-negotiable rather than optional.

How should rest periods be structured to prevent Hexarelin receptor downregulation?

The most evidence-consistent approach is a cyclic protocol: four to six weeks of active administration followed by a two-to-four-week rest period to allow GHS-R1a receptor density to recover. During the rest interval, a GHRH analogue without GHS-R1a activity (e.g. Mod GRF 1-29) may be continued without accelerating Hexarelin-specific desensitisation. Reintroducing Hexarelin after a confirmed washout typically restores near-baseline GH pulse responsiveness.

How do I reconstitute and store Bio-Peptide Hexarelin 10mg/vial after opening?

Reconstitute the lyophilised powder with bacteriostatic water — typically 1–2 mL per vial — injected slowly down the vial wall to avoid foaming. Use an insulin syringe (0.3 mL / 29–31 gauge) for precise sub-milligram dosing. Once reconstituted, store the vial refrigerated at 2–8 °C and use within 21–28 days. Avoid freeze-thaw cycling; unreconstituted lyophilised vials may be stored at room temperature away from light.

What makes the 10mg/vial concentration a practical choice for a Hexarelin cycling protocol?

At 10 mg per vial, a single Bio-Peptide vial provides sufficient compound for a full four-to-six-week administration phase at typical research doses of 100–200 mcg per injection, three times daily — without requiring multiple vials or leaving significant product unused. This concentration is the highest available in this format and eliminates the partial-vial wastage common with lower-fill options, making it the most cost-efficient choice for structured on/off tolerance management. (2) angle_used

Manufacturer

What differentiates Bio-Peptide from the broader European research-compound field is not a single quality decision but a structural commitment made before commercial operations began: every batch produced under the Bio-Peptide label would require an independent laboratory to confirm both its molecular identity and its endotoxin status before release — full stop. That commitment translated operationally into two fixed verification steps: HPLC sequence confirmation to establish compound identity and purity percentage, and a LAL (Limulus Amebocyte Lysate) endotoxin screen to certify safety for research handling. Neither test is conducted in-house; both are commissioned from external analytical laboratories, with the resulting certificates linked to specific batch identifiers and made available as traceable product documentation. The manufacturing environment itself is governed by cGMP-aligned protocols — covering sourcing of raw peptide precursors, synthesis conditions, lyophilisation parameters, and final vial presentation — ensuring that the verified compound reaches researchers in the same state the laboratory confirmed.